Hepatorenal Syndrome Market

DelveInsight’s ‘Hepatorenal Syndrome (HRS) – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Hepatorenal Syndrome (HRS), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hepatorenal Syndrome (HRS) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted HRS symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Hepatorenal Syndrome (HRS) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Hepatorenal Syndrome (HRS) Disease Understanding and Treatment Algorithm

Hepatorenal Syndrome (HRS) Overview

Hepatorenal syndrome (HRS) is a serious complication of liver cirrhosis with a critically poor prognosis. The pathophysiological hallmark is severe renal vasoconstriction, resulting from complex changes in splanchnic and general circulations as well as systemic and renal vasoconstrictors and vasodilators. HRS always develops in the setting of advanced circulatory dysfunction, and it is always accompanied by ascites and usually by hyponatremia.


HRS definition has been updated recently by the International Ascites Club (IAC) under Kidney Disease Improving Global Outcomes (KDIGO) acute kidney injury (AKI) classification. Recent changes in terminology have led to acute or type I HRS being referred to as AKI-HRS and chronic or type II HRS as chronic kidney disease (CKD)-HRS.


The modification of AKI definition has also led to a change in HRS’s diagnostic criteria. The new diagnostic criteria are based on AKI stages, and there is no need to reach a specific serum creatinine threshold. As per these new criteria, treatment with vasoconstrictors and albumin for HRS management will be started at lower serum creatinine values, with expected higher response rates.


The clinical implications of the newly proposed diagnostic criteria based on the dynamic, serial changes in serum Cr conforming to Acute Kidney Injury Network (AKIN), KDIGO clinical practice guidelines for AKI, Acute Dialysis Quality Initiative (ADQI), and IAC classification systems and revised recommendations of IAC remain unclear. These new diagnostic criteria will certainly result in more hospitalized patients with cirrhosis deemed to have AKI, but whether this will result in earlier treatment and improved outcomes is not known. Renal biomarkers, particularly associated with metabolomic profiling, may ultimately prove to be helpful in more precisely establishing a diagnosis of HRS, but they currently appear to be of limited, practical clinical value.


Hepatorenal Syndrome (HRS) Diagnosis and Treatment

It covers the details of conventional and current medical therapies, and diagnosis available in the Hepatorenal Syndrome (HRS) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Hepatorenal Syndrome (HRS) market report gives a thorough understanding of HRS symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides HRS symptoms of treatment algorithms and treatment guidelines for HRS symptoms in the US, Europe, and Japan.

Hepatorenal Syndrome (HRS) Epidemiology

The epidemiology division’s Hepatorenal Syndrome symptoms provides insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hepatorenal Syndrome (HRS) epidemiology segmented as the Total Incident cases of Hepatorenal Syndrome (HRS), Diagnosed Incident Cases of Hepatorenal Syndrome (HRS), and Type-specific cases of Hepatorenal Syndrome (HRS). The report includes the Incident scenario of HRS symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Hepatorenal Syndrome (HRS) Epidemiology

The epidemiology segment also provides the Hepatorenal Syndrome (HRS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total 7MM incident cases of Hepatorenal Syndrome (HRS) were 282,616 in 2020.

Hepatorenal Syndrome (HRS) Drug Chapters

The drug chapter segment of the Hepatorenal Syndrome (HRS) report encloses the detailed analysis of HRS marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Hepatorenal Syndrome (HRS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


The mainstay of treatment remains vasopressor therapy with albumin to reverse splanchnic vasodilation and improve RBF. Vasoconstrictor therapy cause constriction of splanchnic vessels, resulting in increasing the effective circulating blood volume, which increases renal perfusion and glomerular filtration. Vasoconstrictors are often combined with albumin to improve their clinical benefits. Vasoconstrictors used for HRS management are terlipressin, noradrenaline, and the combination of midodrine + octreotide.

Products detail in the report…


Hepatorenal Syndrome (HRS) Emerging Drugs


BIV201 (BioVie) is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension. According to the company, continuous infusion dosing a new treatment paradigm terlipressin given by continuous infusion is better tolerated than intravenous boluses in type 1 HRS treatment. Moreover, it is effective at lower doses. The drug has also received Orphan Drug designations for ascites and HRS with potential 7 years market exclusivity, which will give the advantage to occupy good market share.

Products detail in the report…

Hepatorenal Syndrome (HRS) Market Outlook

The Hepatorenal Syndrome (HRS) market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Hepatorenal Syndrome (HRS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.


This segment gives a thorough detail of Hepatorenal Syndrome (HRS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, Hepatorenal Syndrome (HRS) market in 7MM is expected to change in the study period 2017–2030.


Key Findings

This section includes a glimpse of the Hepatorenal Syndrome (HRS) market in 7MM. The market size of HRS in the seven major markets was found to be USD 589.67 million in 2020 and market is estimated to increase at a CAGR of 1.17% for the study period (2017–2030).


The United States Market Outlook

This section provides a total of Hepatorenal Syndrome (HRS) market size and market size by therapies in the United States.


The United States accounts for the highest HRS market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


As terlipressin is currently not available in the USA, other vasoconstrictors like norepinephrine, midodrine, and octreotide, are used to treat HRS. Norepinephrine, a catecholamine with predominantly alpha-adrenergic activity, is an inexpensive alternative and widely used as an infusion for HRS treatment. Midodrine (an α1-agonist drug) is usually administered in combination with octreotide (a somatostatin analog) and albumin, and it represents the current standard-of-care in the United States.


The administration of norepinephrine plus albumin has been investigated in the treatment of HRS-1. It was shown to be as effective as terlipressin in the HRS treatment in several trials. Currently, norepinephrine in treating HRS is limited by the need for a central venous line and continuous monitoring, thus rendering the treatment unfeasible outside intensive care units.


EU-5 Countries: Market Outlook

The total Hepatorenal Syndrome (HRS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Terlipressin is the most common vasopressor used and acts on the V1 receptors on vascular smooth muscle cells. Despite the increasing body of evidence supporting its use, Terlipressin has not been approved for use in the United States yet. It is currently marketed in Europe for the treatment of HRS.


Japan Market Outlook

The total Hepatorenal Syndrome (HRS) market size and market size by therapies in Japan are also mentioned.

Hepatorenal Syndrome (HRS) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Hepatorenal Syndrome (HRS) market uptake by drugs; patient uptake by therapies; and drug sales.


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Hepatorenal Syndrome (HRS) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hepatorenal Syndrome (HRS) key players involved in developing targeted therapeutics.

Major players include Terlipressin (Mallinckrodt) and BIV201 (BioVie) being assessed as potential therapies to be available in the market in the coming future.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Hepatorenal Syndrome (HRS) emerging therapies.

Reimbursement Scenario in Hepatorenal Syndrome (HRS)

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process

KOL- Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Hepatorenal Syndrome (HRS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Hepatorenal Syndrome (HRS) market trend. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Hepatorenal Syndrome (HRS) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Hepatorenal Syndrome (HRS), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Hepatorenal Syndrome (HRS) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hepatorenal Syndrome (HRS) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hepatorenal Syndrome (HRS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hepatorenal Syndrome (HRS) market

Report Highlights

  • In the coming years, Hepatorenal Syndrome (HRS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hepatorenal Syndrome (HRS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for HRS. The launch of emerging therapies will significantly impact the Hepatorenal Syndrome (HRS) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for HRS.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hepatorenal Syndrome (HRS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Hepatorenal Syndrome (HRS) Pipeline Analysis
  • Hepatorenal Syndrome (HRS) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Hepatorenal Syndrome (HRS) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Hepatorenal Syndrome (HRS) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Hepatorenal Syndrome (HRS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Hepatorenal Syndrome (HRS) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Hepatorenal Syndrome (HRS) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017–2030)?
  • What are the market's key findings across 7MM and which country will have the largest Hepatorenal Syndrome (HRS) market Size during the forecast period (2017–2030)?
  • At what CAGR, the Hepatorenal Syndrome (HRS) market is expected to grow by 7MM during the forecast period (2017–2030)?
  • What would be the Hepatorenal Syndrome (HRS) market outlook across the 7MM during the forecast period (2017–2030)?
  • What would be the Hepatorenal Syndrome (HRS) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of the Hepatorenal Syndrome (HRS)?
  • What is the historical Hepatorenal Syndrome (HRS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What would be the forecasted patient pool of Hepatorenal Syndrome (HRS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Hepatorenal Syndrome (HRS)?
  • Out of all 7MM countries, which country would have the highest incident population of Hepatorenal Syndrome (HRS) during the forecast period (2017–2030)?
  • At what CAGR the population is expected to grow by 7MM during the forecast period (2017–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Hepatorenal Syndrome (HRS)?
  • What are the current treatment guidelines for treating Hepatorenal Syndrome (HRS) in the USA, Europe, and Japan?
  • What are the Hepatorenal Syndrome (HRS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Hepatorenal Syndrome (HRS)?
  • How many therapies are developed by each company for the treatment of Hepatorenal Syndrome (HRS)?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Hepatorenal Syndrome (HRS)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hepatorenal Syndrome (HRS) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hepatorenal Syndrome (HRS) and their status?
  • What are the key designations that have been granted for the emerging therapies for Hepatorenal Syndrome (HRS)?
  • What are the global historical and forecasted market of Hepatorenal Syndrome (HRS)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Hepatorenal Syndrome (HRS) market
  • To understand the future market competition in the Hepatorenal Syndrome (HRS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Hepatorenal Syndrome (HRS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Hepatorenal Syndrome (HRS) market
  • To understand the future market competition in the Hepatorenal Syndrome (HRS) market

1. Key Insights

2. Hepatorenal Syndrome (HRS) Market Overview at a Glance

2.1. Market Share (%) Distribution of Hepatorenal Syndrome (HRS) in 2017

2.2. Market Share (%) Distribution of Hepatorenal Syndrome (HRS) in 2030

3. Executive Summary

4. Disease Background and Overview

4.1. Introduction

4.2. Symptoms

4.3. Etiology and Risk Factors

4.4. Pathophysiology

4.5. Precipitating Factors

4.6. Classification and Diagnosis Criteria of Hepatorenal Syndrome

5. Epidemiology and Patient Population

5.1. Key Findings

6. Country-wise Epidemiology of Hepatorenal Syndrome: 7MM

7. Assumptions and rationale

7.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in 7MM

7.2. The United States

7.2.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in the United States

7.2.2. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in the United States

7.2.3. Type-specific Incidence of Hepatorenal Syndrome (HRS) in the United States

7.3. EU5 Countries

7.3.1. Germany

7.3.2. Total Incident Cases of Hepatorenal Syndrome (HRS) in Germany

7.3.3. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Germany

7.3.4. Type-specific Incident of Hepatorenal Syndrome (HRS) in Germany

7.4. France

7.4.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in France

7.4.2. Diagnosed incidence of Hepatorenal Syndrome (HRS) in France

7.4.3. Type-specific Incidence of Hepatorenal Syndrome (HRS) in France

7.5. Italy

7.5.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in Italy

7.5.2. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Italy

7.5.3. Type-specific Incident of Hepatorenal Syndrome (HRS) in Italy

7.6. Spain

7.6.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in Spain

7.6.2. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Spain

7.6.3. Type-specific Incident of Hepatorenal Syndrome (HRS) in Spain

7.7. United Kingdom

7.7.1. Total Incident Cases of Hepatorenal Syndrome (HRS) in the United Kingdom

7.7.2. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in the United Kingdom

7.7.3. Type-specific Incidence of Hepatorenal Syndrome (HRS) in the United Kingdom

7.7.4. Japan

7.7.5. Total Incident Cases of Hepatorenal Syndrome (HRS) in Japan

7.7.6. Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Japan

7.7.7. Type-specific Incidence of Hepatorenal Syndrome (HRS) in Japan

8. Treatment and Management

8.1. Management of Type I (HRS-AKI)

8.1.1. The new algorithm for the management of AKI HRS and implications for therapy

8.2. Management of Type-II (HRS-CKD)

9. Unmet Needs

10. Organizations

11. Patient Journey

12. Emerging Therapies

12.1. Key cross competition

12.2. Terlipressin: Mallinckrodt

12.2.1. Drug Description

12.2.2. Product Developmental Activities

12.2.3. Other Developmental Activities

12.2.4. Clinical Development

12.2.5. Clinical Trials Information

12.2.6. Safety and Efficacy

12.2.7. Product Profile

12.3. BIV201: BioVie

12.3.1. Product Description

12.3.2. Other Developmental Activities

12.3.3. Product Profile

13. Other Potential Therapies

13.1. Ifetroban: Cumberland Pharmaceuticals

13.1.1. Product Description

13.1.2. Other Developmental Activities

13.1.3. Clinical Development

13.1.4. Clinical Trials Information

13.1.5. Product Profile

14. Hepatorenal Syndrome (HRS): Seven Major Market Analysis

14.1. Key Findings

14.2. Market Size of Hepatorenal Syndrome (HRS) in 7MM

15. Seven Major Market Outlook

15.1. The United States Market Size

15.1.1. Total Market Size of Hepatorenal Syndrome (HRS) in the United States

15.1.2. Market Size of Hepatorenal Syndrome (HRS) by Therapies in the United States

15.2. Germany

15.2.1. The total market size of Hepatorenal Syndrome (HRS) in Germany

15.2.2. Market size of Hepatorenal Syndrome (HRS) by Therapies in Germany

15.3. France

15.3.1. The total market size of Hepatorenal Syndrome (HRS) in France

15.3.2. The market size of Hepatorenal Syndrome (HRS) by Therapies in France

15.4. Italy

15.4.1. The total market size of Hepatorenal Syndrome (HRS) in Italy

15.4.2. The market size of Hepatorenal Syndrome (HRS) by Therapies in Italy

15.5. Spain

15.5.1. Total Market Size of Hepatorenal Syndrome (HRS) in Spain

15.5.2. The market size of Hepatorenal Syndrome (HRS) by Therapies in Spain

15.6. United Kingdom

15.6.1. The total market size of Hepatorenal Syndrome (HRS) in the United Kingdom

15.6.2. The market size of Hepatorenal Syndrome (HRS) by Therapies in the UK

15.7. Japan

15.7.1. The total market size of Hepatorenal Syndrome (HRS) in Japan

15.7.2. The market size of Hepatorenal Syndrome (HRS) by Therapies in Japan

16. Market Drivers

17. Market Barriers

18. Market Access and Reimbursement

19. SWOT Analysis for HRS

20. Case studies

20.1. A Case of Type I Hepatorenal Syndrome Treated with Vasopressin

20.2. Hepatorenal Syndrome: Case Representation

20.3. A Case of Hepatorenal Syndrome and Abdominal Compartment Syndrome with High Renal Congestion

21. Bibliography

22. Appendix

22.1. Report Methodology

22.2. Reference

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

List of Table

Table 1: New classification of HRS subtypes.

Table 2: New diagnostic criteria for HRS-AKI

Table 3: Total Incident Cases of Hepatorenal Syndrome (HRS) in 7MM (2017–2030)

Table 4: Total Incident Cases of Hepatorenal Syndrome (HRS) in the United States (2017–2030)

Table 5: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in the United States (2017–2030)

Table 6: Type-specific Incidence of Hepatorenal Syndrome (HRS) in the US (2017–2030)

Table 7: Total Incident Cases of Hepatorenal Syndrome (HRS) in Germany (2017–2030)

Table 8: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Germany (2017–2030)

Table 9: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Germany (2017–2030)

Table 10: Total Incident Cases of Hepatorenal Syndrome (HRS) in France (2017–2030)

Table 11: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in France (2017–2030)

Table 12: Type-specific Incidence of Hepatorenal Syndrome (HRS) in France (2017–2030)

Table 13: Total Incident Cases of Hepatorenal Syndrome (HRS) in Italy (2017–2030)

Table 14: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Italy (2017–2030)

Table 15: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Italy (2017–2030)

Table 16: Total Incident Cases of Hepatorenal Syndrome (HRS) in Spain (2017–2030)

Table 17: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Spain (2017–2030)

Table 18: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Spain (2017–2030)

Table 19: Total Incident Cases of Hepatorenal Syndrome (HRS) in the United Kingdom (2017–2030)

Table 20: Diagnosed Cases of Hepatorenal Syndrome (HRS) in the United Kingdom (2017–2030)

Table 21: Type-specific Incidence of Hepatorenal Syndrome (HRS) in the UK (2017–2030)

Table 22: Total Incident Cases of Hepatorenal Syndrome (HRS) in Japan (2017–2030)

Table 23: Diagnosed incidence of Hepatorenal Syndrome (HRS) in Japan (2017–2030)

Table 24: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Japan (2017–2030)

Table 25: Key cross competition - Emerging Therapies

Table 26: Terlipressin, Clinical Trial Description, 2021

Table 27: Ifetroban, Clinical Trial Description, 2021

Table 28: Market Size of Hepatorenal Syndrome (HRS) in 7MM in USD Million (2017–2030)

Table 29: The US Market Size of Hepatorenal Syndrome (HRS) in USD Million (2017–2030)

Table 30: US Market Size of Hepatorenal Syndrome (HRS) in USD Million (2017–2030)

Table 31: Market Size of Hepatorenal Syndrome (HRS) in Germany, USD Millions (2017–2030)

Table 32: Germany Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)

Table 33: Market Size of Hepatorenal Syndrome (HRS) associated in France, USD Millions (2017–2030)

Table 34: France Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)

Table 35: Italy Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)

Table 36: Italy Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)

Table 37: Market Size of Hepatorenal Syndrome (HRS) in Spain, USD Millions (2017–2030)

Table 38: Spain Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)

Table 39: Market Size of Hepatorenal Syndrome (HRS) in the UK, USD Millions (2017–2030)

Table 40: UK Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)

Table 41: Market Size of Hepatorenal Syndrome (HRS) in Japan, USD Millions (2017–2030)

Table 42: Japan Market Size of Hepatorenal Syndrome (HRS) by Therapies in USD Million (2017–2030)

List of Figures

Figure 1: Symptoms of HRS

Figure 2: New Pathophysiological hypothesis of acute decompensation and the development of organ dysfunction in patients with cirrhosis

Figure 3: Mechanisms of renal injury potentially involved in HRS-AKI in patients with cirrhosis

Figure 4: Role of a precipitating factor in HRS

Figure 5: Criteria for the diagnosis of AKI based on absolute or percentage increase of serum creatinine-based on the time of initial presentation (T0)

Figure 6: Criteria for the diagnosis of HRS-NAKI based on the time of initial presentation (T0)

Figure 7: Total Incident Cases of Hepatorenal Syndrome (HRS) in 7MM (2017–2030)

Figure 8: Total Incident Cases of Hepatorenal Syndrome in the United States (2017–2030)

Figure 9: Diagnosed Incidence of Hepatorenal Syndrome in the United States (2017–2030)

Figure 10: Type-specific Diagnosed Incidence of Hepatorenal Syndrome (HRS) in the US (2017–2030)

Figure 11: Total Incident Cases of Hepatorenal Syndrome (HRS) in Germany (2017–2030)

Figure 12: Diagnosed incidence of Hepatorenal Syndrome (HRS) in Germany (2017–2030)

Figure 13: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Germany (2017–2030)

Figure 14: Total Incident Cases of Hepatorenal Syndrome (HRS) in France (2017–2030)

Figure 15: Diagnosed incidence of Hepatorenal Syndrome (HRS) in France (2017–2030)

Figure 16: Type-specific Incidence of Hepatorenal Syndrome (HRS) in France (2017–2030)

Figure 17: Total Incident Cases of Hepatorenal Syndrome (HRS) in Italy (2017–2030)

Figure 18: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Italy (2017–2030)

Figure 19: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Italy (2017–2030)

Figure 20: Total Incident Cases of Hepatorenal Syndrome (HRS) in Spain (2017–2030)

Figure 21: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Spain (2017–2030)

Figure 22: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Spain (2017–2030)

Figure 23: Total Incident Cases of Hepatorenal Syndrome in the UK (2017–2030)

Figure 24: Diagnosed Incidence of Hepatorenal Syndrome in the UK (2017–2030)

Figure 25: Type-specific Incidence of Hepatorenal Syndrome (HRS) in the UK (2017–2030)

Figure 26: Total Incident Cases of Hepatorenal Syndrome (HRS) in Japan (2017–2030)

Figure 27: Diagnosed Incidence of Hepatorenal Syndrome (HRS) in Japan (2017–2030)

Figure 28: Type-specific Incidence of Hepatorenal Syndrome (HRS) in Japan (2017–2030)

Figure 29: Algorithm for the management of AKI in patients with cirrhosis.

Figure 30: Unmet Needs

Figure 31: Market Size of Hepatorenal Syndrome (HRS) in USD Million (2017–2030)

Figure 32: Market Size of Hepatorenal Syndrome (HRS) in the US, USD Millions (2017–2030)

Figure 33: Market Size of Hepatorenal Syndrome (HRS) in the US by therapies, USD Millions (2017–2030)

Figure 34: Market Size of Hepatorenal Syndrome (HRS) in Germany, USD Millions (2017–2030)

Figure 35: Market Size of Hepatorenal Syndrome (HRS) in Germany by therapies, USD Millions (2017–2030)

Figure 36: Market Size of Hepatorenal Syndrome (HRS) in France, USD Millions (2017–2030)

Figure 37: Market Size of Hepatorenal Syndrome (HRS) in France by therapies, USD Millions (2017–2030)

Figure 38: Market Size of Hepatorenal Syndrome (HRS) in Italy, USD Millions (2017–2030)

Figure 39: Market Size of Hepatorenal Syndrome in Italy by therapies, USD Millions (2017–2030)

Figure 40: Market Size of Hepatorenal Syndrome (HRS) in Spain, USD Millions (2017–2030)

Figure 41: Market Size of Hepatorenal Syndrome (HRS) in Spain by therapies, USD Millions (2017–2030)

Figure 42: Market Size of Hepatorenal Syndrome (HRS) in the UK, USD Millions (2017–2030)

Figure 43: Market Size of Hepatorenal Syndrome (HRS) in the UK by therapies, USD Millions (2017–2030)

Figure 44: Market Size of Hepatorenal Syndrome (HRS) in Japan, USD Millions (2017–2030)

Figure 45: Market Size of Hepatorenal Syndrome (HRS) in Japan by therapies, USD Millions (2017–2030)

Figure 46: Market Drivers

Figure 47: Market Barriers

 Mallinckrodt

BioVie

Cumberland Pharmaceuticals

  • Tags:
  • Hepatorenal Syndrome market
  • Hepatorenal Syndrome market resear...
  • Hepatorenal Syndrome Companies
  • Hepatorenal Syndrome market trends
  • Hepatorenal Syndrome market foreca...
  • Hepatorenal Syndrome market share
  • Hepatorenal Syndrome pipeline
  • Hepatorenal Syndrome treatment alg...
  • Hepatorenal Syndrome drugs
  • Hepatorenal Syndrome sales forecas...
  • Hepatorenal Syndrome market size
  • Hepatorenal Syndrome disease
  • Hepatorenal Syndrome epidemiology
  • Hepatorenal Syndrome

Forward to Friend

Need A Quote